Bio-Path Holdings Inc.

04/18/2024 | Press release | Distributed by Public on 04/18/2024 08:35

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients